Autoimmune leukopenia is a rare disorder but may cause severe life-threatening infections. Here we report a case involving a 58-year-old male with a history of severe autoimmune leukopenia that was highly refractory to therapies targeting T and B linage cells but had a durable response to daratumumab. This case management suggested that targeting plasma cells may be considered for refractory autoimmune leukopenia.

Seiter:Rigel: Membership on an entity's Board of Directors or advisory committees; Abbvie: Membership on an entity's Board of Directors or advisory committees; BMS: Membership on an entity's Board of Directors or advisory committees; CTI: Speakers Bureau; Incyte: Speakers Bureau; Alexion: Honoraria; Servier: Speakers Bureau; Novartis: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Blueprint: Speakers Bureau. Steinberg:MorphoSys: Membership on an entity's Board of Directors or advisory committees; Jazz Pharmaceuticals: Speakers Bureau. Reilly:RenBio: Consultancy. Liu:Beigene: Speakers Bureau; Rigel: Speakers Bureau.

daratumumab is anti-CD38 monoclonal antibody. Targeting plasma cell may be considered for refractory autoimmune leukopenia.

This content is only available as a PDF.
2023
Sign in via your Institution